Blog
Architecture review before implementation
Implementation scope and rollout planning
Clear next-step recommendation
Polygenic risk scores (PRS) promise personalized health forecasts but fail for underrepresented groups due to biased genomic training data.
Polygenic risk scores (PRS) fail for most global populations because they are trained predominantly on genetic data from individuals of European ancestry. This creates a precision medicine paradox where 'personalized' predictions are only accurate for a narrow demographic slice.
Training data bias is systemic. Major biobanks like UK Biobank and genome-wide association studies (GWAS) have historically over-sampled European cohorts. This means the single nucleotide polymorphisms (SNPs) identified as significant for disease risk are not generalizable across ancestries, leading to poor predictive performance in African, Asian, and Indigenous populations.
The technical consequence is model collapse. A PRS model trained on non-diverse data exhibits high variance in effect size estimates when applied to new populations. For example, a score predicting coronary artery disease risk developed in Europeans can be statistically useless for individuals of South Asian descent, as highlighted in studies from the Broad Institute.
This bias perpetuates health disparities. Deploying these scores in clinical decision support systems or for patient stratification in trials risks misdiagnosis and unequal allocation of preventive care. It transforms a tool for equity into an engine of exclusion, a core challenge in building ethical AI for genomics.
Solving this requires federated learning. Techniques like federated learning enable model training across distributed, diverse datasets without centralizing sensitive genomic data, directly addressing the privacy and bias issues outlined in our guide on federated learning for patient data.
Evidence: Performance gaps are quantifiable. Research in Nature Genetics shows predictive accuracy for breast cancer PRS drops by over 60% when applied from European to African-ancestry populations. This isn't a marginal error; it's a fundamental failure of the underlying data foundation.
Polygenic risk scores trained on non-diverse populations produce inaccurate predictions and perpetuate health disparities, creating hidden financial and ethical liabilities.
Most large-scale genomic studies, like the UK Biobank, are overwhelmingly of European ancestry. Models trained on this data fail to generalize, creating a predictive performance gap of 20-40% for underrepresented populations. This isn't just an accuracy issue; it's a reproducibility crisis for global drug development.
You cannot centralize sensitive global genomic data. Federated learning enables model training across institutions without moving raw data, solving privacy and sovereignty challenges. For data-scarce populations, high-fidelity synthetic data generation creates statistically representative cohorts for robust model development, a technique covered in our guide to synthetic data generation.
A drug developed using biased polygenic risk scores may show efficacy only in a subset of the population, leading to Phase III trial failures that cost $50M-$100M+. Worse, deploying inaccurate scores in clinical care opens the door to medical malpractice and discrimination lawsuits. This makes explainable AI (XAI) and bias auditing non-negotiable components of the AI TRiSM framework.
Moving beyond spurious correlation requires causal inference models that identify true biological mechanisms. Graph Neural Networks (GNNs) are uniquely suited to model the complex, non-linear relationships within gene-disease networks, uncovering therapeutic pathways that correlation-based PRS models miss. This approach is foundational for AI-guided target identification.
Polygenic risk scores trained on non-diverse genomic datasets produce systematically inaccurate and inequitable health predictions for underrepresented populations.
Biased training data directly sabotages the clinical utility of polygenic risk scores (PRS) by creating models that fail for anyone not represented in the original cohort. PRS models, built using statistical frameworks like Plink or REGENIE, calculate disease risk by summing the effects of thousands of genetic variants; if those variant-disease associations are derived almost exclusively from European-ancestry genomes, the resulting scores are statistically invalid for other groups.
The problem is systemic, not incidental. Landmark biobanks like the UK Biobank are overwhelmingly composed of participants of European descent. This creates a foundational skew in the genome-wide association studies (GWAS) that power PRS, meaning the 'risk' alleles identified are specific to one population's genetic architecture and linkage disequilibrium patterns.
The consequence is predictive failure. A PRS for type 2 diabetes trained on European data can misclassify risk for individuals of South Asian or African ancestry by over 50%. This isn't a minor error—it's a clinical liability that perpetuates health disparities by denying accurate preventative care to underrepresented groups.
Evidence: A 2023 study in Nature demonstrated that PRS accuracy, measured by AUC, drops by an average of 0.15 to 0.30 when applied to populations not represented in the training data. This performance collapse renders the scores clinically useless and ethically dangerous.
Solving this requires a sovereign data strategy. Organizations must build diverse, geopatriated genomic datasets or leverage federated learning frameworks to train models across global cohorts without centralizing sensitive data. This aligns with our work on sovereign AI infrastructure and is a prerequisite for equitable precision medicine.
A comparison of polygenic risk score (PRS) performance across ancestries, highlighting the direct impact of non-diverse training data on predictive accuracy and clinical utility.
| Performance Metric | European Ancestry Cohorts | African Ancestry Cohorts | East Asian Ancestry Cohorts |
|---|---|---|---|
Average AUC-ROC for Coronary Artery Disease | 0.81 | 0.63 | 0.75 |
Variance Explained (R²) for Type 2 Diabetes | 12.4% | 3.1% | 8.7% |
Odds Ratio per Standard Deviation (Breast Cancer) | 1.45 | 1.18 | 1.32 |
Required Cohort Size for Equivalent Power | 100k |
| 150k |
Proportion of GWAS Discovery Samples | 78% | 2% | 14% |
Transferability (Portability) Score | |||
Calibration Error (Brier Score) | 0.09 | 0.21 | 0.13 |
Clinically Actionable Risk Stratification Rate | 22% | 6% | 15% |
Polygenic risk scores trained on non-diverse genomic datasets produce inaccurate predictions for underrepresented groups, perpetuating health disparities and creating systemic financial liabilities.
Over 78% of participants in genome-wide association studies (GWAS) are of European descent. This creates models that fail to generalize, with prediction accuracy dropping by ~40-60% for African, Hispanic, and Indigenous populations.
Federated learning enables model training across global biobanks and hospitals without transferring raw genomic data, solving privacy and data sovereignty challenges.
Replace black-box statistical models with causal inference frameworks that identify true biological mechanisms, not just population-specific correlations.
Drug targets and clinical trial designs based on biased PRS lead to late-stage trial failures and therapies ineffective for global markets.
Generate privacy-preserving synthetic datasets that mirror the statistical properties of real, diverse genomic cohorts without privacy risk.
Regulators (FDA, EMA) now demand causal reasoning and fairness audits for AI/ML in SaMD. Unexplainable, biased models will not clear clinical validation.
The common excuse of 'data availability' for biased genomic models is a technical failure that perpetuates health disparities and produces inaccurate predictions.
Data availability is not a justification for bias; it is a solvable engineering problem. Models like polygenic risk scores (PRS) trained on non-diverse cohorts, such as the UK Biobank, fail for underrepresented populations because they learn spurious correlations specific to the training data's genetic ancestry. This creates a technical debt of inequity that is expensive to fix post-deployment.
The fallacy confuses quantity with representativeness. A model trained on a million genomes from a single population has less generalizable power than one trained on 100,000 genomes from five ancestries. Federated learning frameworks like NVIDIA FLARE or OpenFL enable training across global biobanks without centralizing data, directly addressing the privacy and diversity challenge.
Bias is a feature, not a bug, of the training pipeline. Standard practices in genomic AI, like using principal component analysis (PCA) for population stratification, often bake in ancestry as a confounding variable. Techniques like counterfactual fairness and adversarial debiasing must be integrated during model development, not as an afterthought.
Evidence: A 2023 study in Nature showed a PRS for coronary artery disease trained on European data had an AUC drop of over 0.15 when applied to South Asian populations. This performance gap represents a direct clinical risk for millions of patients. Solving this requires a commitment to deliberate data acquisition and techniques like synthetic data generation to augment underrepresented groups, a core component of our work in synthetic data for clinical trials.
The operational cost is recursive. A biased model deployed in a healthcare system generates flawed predictions, which are then used to make decisions that further skew future data collection. Breaking this cycle requires MLOps for continuous monitoring of performance across demographic subgroups and the architectural flexibility of a hybrid cloud strategy to incorporate diverse, sovereign data sources.
Polygenic risk scores trained on non-diverse populations perpetuate health disparities and produce inaccurate predictions for underrepresented groups. Here are actionable technical solutions to mitigate bias.
Training data from biobanks like UK Biobank is overwhelmingly European, causing PRS models to fail for non-European ancestries. This leads to misdiagnosis risk and widening health equity gaps.\n- Consequence: PRS accuracy can drop by >50% for African, Hispanic, and Indigenous populations.\n- Impact: Perpetuates systemic bias in preventive care and clinical trial eligibility.
Train models across distributed, privacy-preserving datasets without centralizing sensitive genomic data. This enables collaboration with global biobanks while complying with GDPR and HIPAA.\n- Key Benefit: Enables model training on globally representative data without patient data leaving its institution.\n- Key Benefit: Solves the data sovereignty challenge, a core principle of our work on Sovereign AI infrastructure.
Use adversarial neural networks to strip ancestry-correlated signals from the model, forcing it to learn only disease-relevant genetic variants. Pair with causal inference models to move beyond spurious correlations.\n- Key Benefit: Reduces ancestry-based prediction disparity by ~70% in benchmark studies.\n- Key Benefit: Aligns with Explainable AI (XAI) principles, making model decisions auditable for regulators, a topic we explore in AI TRiSM.
Generate privacy-preserving synthetic genomes that mirror the statistical properties of real, underrepresented populations using Generative Adversarial Networks (GANs) or diffusion models.\n- Key Benefit: Creates balanced training cohorts without privacy or consent barriers.\n- Key Benefit: Enables stress-testing of PRS models across a full spectrum of simulated ancestries, a technique detailed in our synthetic data generation insights.
Unexplainable PRS models create liability and hinder clinical adoption. Regulators demand causal reasoning, not just statistical association, for target validation and patient risk stratification.\n- Consequence: Models cannot be debugged for spurious ancestry linkages.\n- Impact: Blocks translation from research to FDA-cleared clinical decision support tools.
Implement robust MLOps pipelines to monitor for model drift as human genomes evolve and new population data emerges. Automate retraining triggers to maintain accuracy across all groups.\n- Key Benefit: Ensures long-term model fairness and performance in production, a core tenet of our MLOps services.\n- Key Benefit: Provides audit trails for model versions, training data, and performance metrics across ancestries.
Enabling Efficiency, Speed & Accuracy
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Polygenic risk scores built on non-diverse data will face regulatory action for perpetuating health disparities and producing invalid predictions.
Polygenic risk scores (PRS) trained on non-diverse genomic data produce invalid clinical predictions for underrepresented populations, triggering imminent regulatory action. The foundational models for these scores rely on datasets like the UK Biobank, which are overwhelmingly of European ancestry. This creates a genomic data gap that systematically misrepresents the genetic architecture of other populations, rendering the scores clinically useless and ethically indefensible.
The core technical failure is population stratification, not algorithmic bias. Standard PRS models assume genetic effects are consistent across ancestries, a flawed premise that amplifies health disparities. A score predicting a 10% risk of Type 2 Diabetes for a European-ancestry individual could indicate a 2% or 25% risk for someone of African or Asian descent, making the tool dangerous for clinical decision-making.
Regulatory bodies like the FDA and EMA will mandate diversity in training data as a precondition for approval. The EU AI Act already classifies high-risk AI systems in healthcare, requiring rigorous bias and fairness auditing. Developers using platforms like TensorFlow Extended (TFX) or MLflow for MLOps must now integrate ancestry-aware validation suites and demonstrate generalizability across global populations, a core tenet of responsible AI TRiSM.
Evidence: A 2023 study in Nature found that PRS accuracy for coronary artery disease dropped by over 60% when applied to African-ancestry populations versus European groups. This performance collapse is a direct result of non-representative training cohorts. Fixing this requires a fundamental shift to inclusive data strategies, such as federated learning on global cohorts, a method detailed in our analysis of federated learning for patient genomic data.
About the author
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
How We Work
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
The first call is a practical review of your use case and the right next step.
